"the company has entered into negotiations concerning a material capital raising"Not exactly a rights issue at 64 cents, sounds more like external finance or cornerstone investor to me....
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%